AMA hops on social media bandwagon

Share this article:

In just over a month, the American Medical Association (AMA) has launched a YouTube channel, a blog written by AMA president James Rohack and a Facebook page.

AMA kicked off its YouTube presence with a video emphasizing the need for healthcare reform, and has since launched three “virtual town hall” videos tackling various aspects of the healthcare reform debate. AMA was an early supporter of the House bill on health reform, and has faced a backlash from some quarters of the medical community as a result.

Physician online community Sermo and the AMA ended their partnership in July after disagreements over the terms of their relationship.

On September 8, AMA announced the launch of a presence on Facebook. Rohack said in a release that the AMA's Facebook page “is a tool for patients and physicians to learn and communicate with each other about the latest health-reform developments.” The Facebook page, which links to the YouTube channel and offers other information, photos and links, currently has 705 “fans.”

Rohack's blog, titled On the Road with Dr. Rohack, launched in late August and is focused on chronicling his travels across the country as an AMA advocate.

In his inaugural post, Rohack reiterated the AMA's stance on health reform and said Congress needs to work together, and encouraged doctors and their patients to visit the AMA's health system reform site.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...